No Data
No Data
Lukang Biochemical: 2024 Annual Performance Forecast
Lifecome Biochemistry (002868.SZ): Expected loss for the year 2024 is between 0.34 billion yuan and -0.39 billion yuan.
According to Gelonghui on January 23, Lifecome Biochemistry (002868.SZ) announced its performance forecast for 2024, expecting revenue of 0.64 billion yuan to -0.65 billion yuan; the Net income attributable to the shareholders of the listed company is estimated to be a loss of 0.39 billion yuan to 0.34 billion yuan, a decrease of 75.82% to 53.28% compared to the same period last year; the Net income attributable to the shareholders of the listed company after deducting non-recurring gains and losses is projected to be a loss of 0.395 billion yuan to 0.345 billion yuan, a decrease of 71.16% to 49.49% compared to the same period last year; the basic EPS is expected to be a loss of 2.51 yuan/share to 2.19 yuan/share. Revenue compared to the same period last year.
Express News | Lifecome Biochemistry: The company's operation is normal.
Lifecome Biochemistry (002868.SZ): Plans to increase capital for Lifecome Yushan through Debt-for-equity Swaps.
Gelonghui, December 25 - Lifecome Biochemistry (002868.SZ) announced that to enhance the financial strength of Lifecome Yushan and optimize its capital structure, promoting its Business development, the company will convert accounts receivable from Lifecome Yushan amounting to 0.15 billion yuan into additional capital. After this capital increase is completed, the registered capital of Lifecome Yushan will increase from 0.1 billion yuan to 0.25 billion yuan. The company will still Hold 100% equity of Lifecome Yushan.
Express News | Lifecome Biochemistry: Increased investment of 0.15 billion yuan in wholly-owned subsidiary.
Express News | Lifecome Biochemistry: plans to borrow 20 million yuan from the controlling Shareholder for daily production Operation.